Traduction de «driven by phasing of clinical » (Néerlandais → Français) :

R&D increased 0.3 percentage points, mainly driven by phasing of clinical trial activities.
Recherche et développement s’est amélioré de 0,3 point, essentiellement à la suite d’un étalement des essais cliniques dans le temps.

R&D improved 0.7 percentage points, mainly driven by phasing of clinical trial activities.
La R&D s’est améliorée de 0,7 point de pourcentage, essentiellement à la suite d’un étalement dans le temps des essais cliniques.

R&D improved 0.3 percentage points, mainly driven by phasing of clinical trial activities.
La R&D s’est améliorée de 0,3 point, essentiellement à la suite d’un étalement dans le temps des essais cliniques.

However, the figures do clearly show that there is a considerable number of early phase trials. There are 7 units in Belgium actively undertaking phase I clinical trials and a number of early phase trials are being conducted in centres where there is expertise in specific clinical areas.
However, the figures do clearly show that there is a considerable number of early phase trials. There are 7 units in Belgium actively undertaking phase I clinical trials and a number of early phase trials are being conducted in centres where there is expertise in specific clinical areas.

Planned to initiate a Phase III clinical development program in chronic coronary heart disease in Q1 2011
Début d’un programme de développement clinique de phase III dans la maladie coronarienne chronique prévu

QAB149 (indacaterol), a bronchodilator in development for Chronic Obstructive Pulmonary Disease (COPD), has been shown in Phase III clinical trials to significantly improve lung function over the currently available treatments formoterol and tiotropium at three months of therapy.
QAB149 (indacatérol), un bronchodilatateur en développement pour traiter la bronchopneumopathie chronique obstructive (BPCO), a montré, dans des essais cliniques de phase III que, au bout de trois mois, il améliorait notablement la fonction pulmonaire par rapport aux traitements à base de formotérol et tiotropium disponibles actuellement.

Phase III data demonstrating a significant delay in tumor progression in patients with metastatic neuroendocrine tumors of the midgut who were treated with Sandostatin LAR were published recently in the “Journal of Clinical Oncology”.
Le «Journal d’Oncologie Clinique» a publié récemment les résultats de l’étude de phase III confirmant que Sandostatine LAR, administré à des patients atteints de tumeurs neuro-endrocrines métastasiques de l’intestin moyen, ralentissait considérablement la progression de la tumeur.

In 2008, there was a significant increase observed in the number of applications for clinical trials and amendments (changes to an existing file) and of the percentage of phase I trials. The absolute number of non-commercial (“academic”) trials remained stable.
In 2008, there was a significant increase observed in the number of applications for clinical trials and amendments (changes to an existing file) and of the percentage of phase I trials. The absolute number of non-commercial (“academic”) trials remained stable.

The number of early phase trials is per capita one of the highest in Europe. Since the publication of the guideline trials for conducting explorative studies in Belgium, in mid June 2007, 25 applications for conducting these clinical trials have been submitted to the FAMHP.
The number of early phase trials is per capita one of the highest in Europe. Since the publication of the guideline trials for conducting explorative studies in Belgium, in mid June 2007, 25 applications for conducting these clinical trials have been submitted to the FAMHP.

- Updated Phase II pivotal study data presented at the American Society of Clinical Oncology and European Hematology Association congresses
- Les résultats mis à jour d'une étude pivot de phase II ont été présentés aux congrès de la Société américaine d'oncologie clinique et de l’Association